Tumor Infiltrating Articles & Analysis
23 news found
The investigators are now actively recruiting participants who have failed first-line therapy for the above-referenced solid tumors. T-Cure licensed the commercial rights of the KK-LC-1 TCR-T therapy and entered into a Cooperative Research and Development Agreement (CRADA) with the NCI in 2020. ...
“Kanya’s experience spans early- to late-stage biotech companies, including gaining product approvals in both liquid and solid tumors, and leading CAR-NK cell therapy programs through the IND process and rapidly demonstrating clinical ...
Armoring cell therapies with potent cytokines such as IL12 is a promising approach to treating solid tumors, but uncontrolled constitutive expression of these payloads has limited their clinical use due to toxicity. ...
Immune-Onc and The University of Texas published pioneering research in Nature illuminating the role of LILRB4 in immune suppression and tumor infiltration in acute myeloid leukemia (AML) and presented the rationale for targeting LILRB4 in solid tumors at the 2021 American Association for Cancer Research (AACR) Annual Meeting. ABOUT IO-202 ...
The data to be presented demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy in a human leukocyte antigen (HLA)-matched, allogeneic patient-derived xenograft (PDX) melanoma model, including greater persistence of cytoTIL15 cells in blood and lymphoid organs, superior tumor growth inhibition ...
In Nature Communications (15 Dec 2021), lead author Yu-Ting Yen and colleagues at the China Medical University and Hospital, Taichung, Taiwan reported that treatment with LB-100 is associated with new antigen production, tumor infiltration of cytotoxic T cells, and enhanced responsiveness to immune checkpoint blockade in mouse models of colorectal, ...
Alpha-1 Biologics, a biotherapeutics company developing innovative treatments for cancers and immune deficiencies, today announced that positive data was published in frontiers in Oncology demonstrating Alphataxin, a small molecule that elevates circulating and tumor-infiltrating CD4+ T cells, suppressed kidney cancer and suppressed metastasis in mice. ...
The data also revealed high T cell engraftment and persistence along with clinical responses which were associated with tumor infiltration. Patient recruitment to the 4th and highest dose level (up to approximately 2.5 billion total transduced cells) for the ACTengine® IMA203 trial is ongoing. ...
All patients were heavily pretreated with a median of 4 lines of prior systemic treatment. 16 patients were evaluable for tumor response analysis according to RECIST 1.1 with at least one post-treatment tumor assessment at the time of data cut-off. ...
The abstract for the poster demonstrates enhanced in vivo potency of Obsidian’s cytoTIL15 product (TIL engineered with membrane-bound IL15) over conventional tumor-infiltrating lymphocytes (TILs) in PDX mouse models. The translation of previously observed in vitro and in vivo persistence of cytoTIL15 TILs, in the absence of IL2, to superior in vivo ...
Details of the poster presentation: Title: cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility Abstract Number: 1008P Session: Investigational Immunotherapy Abstract Summary: Tumor-infiltrating lymphocytes (TILs) have generated promising data in ...
The trial demonstrated that the therapy was safe and well-tolerated and induced T cell responses against multiple tumor targets. Robust immune responses by patients correlated to clinical benefits. ...
The combined data readout during early phases of dose escalation for the ACTengine® programs, IMA201, IMA202 and IMA203, indicated first anti-tumor activity with tumor shrinkage observed in 8 out of 10 patients including one unconfirmed partial response as of data cut-off. This was consistent with the observed robust engraftment, persistence and ...
The abstract for the poster describes how Obsidian’s cytoTIL15 product (cytoTIL™ therapy engineered with mbIL15) demonstrates enhanced in vivo performance in the absence of IL-2, paving the way for more durable efficacy and improved safety in patients with solid tumor malignancies, and has been published in Molecular Therapy. Details of the poster: Title: ...
The Company expects to submit an IND in mid-2022 for its lead cytoTIL™ program, a novel engineered tumor infiltrating lymphocyte therapy armored with regulated membrane-bound IL15 that does not require patients to receive toxic IL2. ...
Sherman Oaks, CA – March 17, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has entered into a clinical research agreement with Rutgers, The State University of New Jersey, to fund a Phase I clinical study testing a TCR-based ...
The µVS Delivery SystemTM is currently verified or in development for the rapid intracellular delivery of nucleic acids and/or protein complexes to immune cells such as T cells, Regulatory T cells, Natural Killer cells and Tumor Infiltrating Lymphocytes with high yield and minimal perturbation of the immune cell state. ...
Obsidian Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. ...
“By controlling the expression of armed payloads like CD40L, Obsidian’s cell therapy candidates may have the potential to overcome tumor microenvironment resistance and unlock the power of cell therapy in solid tumors and other ...
Secondary endpoints included anti-tumor effects and cellular immune response, plus overall survival. To identify immunological and molecular signatures of responses, three serial liver biopsies (before, during, and after virotherapy) allowed for in-depth analyses of pathological tumor characteristics, tumor-infiltrating immune ...